10.6092/issn.2038-3460/17093
In this contribution, we take a look at the future of stem cell research, with particular emphasis on human embryonic stem cells and induced Pluripotent Stem Cells (iPS). Their implications in terms of ethical and social issues are discussed through interviews with two top Italian scientists, Elena Cattaneo and Giuseppe Testa. In light of their answers, the introduction reflects on how stem cells research, interpreted from an STS perspective, allows us to observe the mutual adaptation between scientific practices which generate multiple biological artifacts, and the many ethical implications which characterize our biotechnological societies.
application/pdf
2038-3460
17093
1
en
Giuseppe Testa
https://creativecommons.org/licenses/by-nc-sa/2.5/
Tecnoscienza – Italian Journal of Science & Technology Studies
symmetry
The Italian Pathways of Stem Cells
Text.Serial.Journal
https://tecnoscienza.unibo.it/
4
Conversations
2013-07-12
2023-06-01
2013-07-12
2023-07-17
145-163
TS
Giuseppe Testa
2013/07/12
10.6092/issn.2038-3460/17093
145
European Institute of Oncology
2038-3460
1
symmetry
en
163
The Italian Pathways of Stem Cells
https://tecnoscienza.unibo.it/article/download/17093/16030
4
                                                                             Conversation

The Italian Pathways of Stem Cells
!
Elena Cattaneo                        Giuseppe Testa               Assunta Viteritti
    University of Milan                 European Institute of     University of Rome Sapienza
                                             Oncology
!
     Abstract In this contribution, we take a look at the future of stem cell re-
     search, with particular emphasis on human embryonic stem cells and induced
     Pluripotent Stem Cells (iPS). Their implications in terms of ethical and social
     issues are discussed through interviews with two top Italian scientists, Elena
     Cattaneo and Giuseppe Testa. In light of their answers, the introduction re-
     flects on how stem cells research, interpreted from an STS perspective, al-
     lows us to observe the mutual adaptation between scientific practices which
     generate multiple biological artifacts, and the many ethical implications which
     characterize our biotechnological societies.

     Keywords ethics; stem cells; standardization; bio-object; symmetry.

     Corresponding author: Assunta Viteritti, Department of Social Sciences,
     University of Rome "Sapienza", Via Salaria 113, 00198, Rome, Italy - Email:
     assunta.viteritti@uniroma1.it.




1. Introduction1
    In 2008, Geesink, Prainsack and Franklin affirmed that: “For stem
cells, the future is now”. This sentence, written 10 years after the publica-
tion of James Alexander Thomson’s article (1998) about ES (Human
Embryonic Stem Cells) in “Science”, became even more explosive in
2009 thanks to the discovery of iPS (Induced Pluripotent Stem Cells) by
Shinya Yamanaka. Stem cells represent what Giuseppe Testa and Elena
Cattaneo build on and call the “Holy Grail” of scientific research. Stem
cells research allows researchers to intervene in the development of cells
in all directions, and this means being able to change the destiny of the
cells – the dream of every scientist.
    As in the best tradition of studies of scientific controversy, the world-
wide picture of stem cells research sees science and society at logger-
heads. Some scientists, together with those sectors of society who pro-

!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1
    Assunta Viteritti wrote the introduction and carried out both the interviews.
!
TECNOSCIENZA
Italian Journal of Science & Technology Studies
4(1) pp. 145-163 - I SSN 2038-3460
www.tecnoscienza.net                                       2013
146                                                         Tecnoscienza - 4 (1)

mote and sponsor adult stem cells research, believe that these cells pro-
duce results similar to those of embryonic stem cells. On the contrary,
other scientists and sectors of society maintain that only human embryon-
ic stem cells are capable of pluripotency, which allows them to differenti-
ate into all types of cell. The juxtaposition between adult and embryonic
stem cells seems to have been integrated, and in some ways overcome,
with the emergence of iPS and the even more promising framework of
cellular reprogramming. However, as the two scientists affirm in the in-
terviews, many aspects of this important discovery still need to be per-
fected, and because of this, alternative pathways have not been set aside
yet.
    Today, many teams focus on the various pathways in stem cells re-
search (adult, embryonic, amniotic, iPS, etc.), which do not exclude each
other. In Italy, where embryonic stem cells cannot be produced, but can
be used (by importing them from abroad), the debate has usually seen on
the one hand the scientific community in favour of experimentation, and
on the other religious authorities mostly against the use of embryonic
stem cells. A similar situation can be found in Austria and Germany,
while in the U.K. their use is legal (though limited to embryos no more
than 14 days old). In 2011, the European Court of Justice defined the use
of embryonic stem cells “immoral”, and it appears likely that patenting
the discoveries deriving from experimentation with this type of cells will
eventually be forbidden (although up to now approximately 100 patents
have been produced in Europe). There are no limitations, however, re-
garding experimentation with (and the use of) iPS. In the U.S., on the
other hand, stem cells research is gathering momentum and producing
results and patents, while in the rest of the world Universities and Asian
research teams, encouraged also by the Nobel prize awarded to Yama-
naka, are entering the field. All this recently prompted two English aca-
demics to speak of experimental ethics (Sleeboom-Faulkner and Simpson
Durham 2013).
    In the two interviews, we wish to offer a panorama of the research in
this field from an Italian viewpoint, through the words of two top Italian
scientists working in their home country. Their work testifies to the dif-
fering, potential pathways which stem cells research has taken throughout
the world. Giuseppe Testa focuses on the iPS perspective, while Elena
Cattaneo points out the use of embryonic stem cells in the neural field,
also observing iPS and their prospects in the diagnostic and clinical field.
The two scientists’ narratives, far from being in contrast, are situated in
an ideal continuum, where the cells’ ethicality is not assumed as a starting
point, rather as an ongoing outcome, an open issue able to pose further
questions.
    Drawing on the two interviews, several aspects concerning the rela-
tionship between stem cells and their social and ethical standing can be
observed from a STS perspective. Firstly, the many types of stem cells,
which have come to the fore in research and literature in the last few
Cattaneo, Testa, and Viteritti                                           147
years, pose a question crucial to STS, namely how to standardize what is
not yet fully known. As Eriksson and Webster (2008) point out, standard-
izing stem cells is an exercise in standardizing different things, which are
as yet unknown: here we are dealing with standardizing unstable
knowledge to be used in biomedical research.
     Another interesting issue posed by stem cells research – a core theme
in laboratory studies and one examined by Karin Knorr-Cetina (1999) – is
that of the artificialization of the natural, meaning a naturalization of re-
search objects in the laboratory. Experimental conditions have an epis-
temic function, in which the nature of biotechnological objects is trans-
formed into different states in order to be produced, observed, handled,
codified, formalized and standardized.
     Stem cells are not ‘natural objects’, but they reach such a status while
being artefacts-in-the-making within biotechnological laboratory practice,
where they assume their second nature as bio-objects. In their diverse ver-
sions, stem cells are, from time to time, epistemic objects (Knorr-Cetina
1999), bio-objects (Vermeule, Tamminen and Webster 2011) and bounda-
ry objects (Star and Griesemer, 1989; Bowker and Star 1999), in relation
to the role they play and the ontology they assume in the scientific prac-
tices in which they are generated and involved.
     A different aspect regards the impact post-genomic research and
translational medicine have had on stem cells (particularly, but not only,
iPS), strengthening genomic research at clinical, molecular and protein
level. As Elena Cattaneo says, the innovation is that: “you take the pa-
tient’s genome into the laboratory, and if you speak with the clinician you
have all his clinical data”: the link is no longer between the scientist and
cells only, as there is much more. Testa tells us that for the first time in
the history of medicine, iPs allows scientists to “tackle human genetic var-
iability experimentally at molecular level”. With the post-genomic phase,
on the one hand the study of cells is placed in a wider context; on the
other hand, the distance separating basic research (the workbench) and
regenerative medicine (the cure) is reduced. In this process, the patient
becomes a kind of active experimenter of knowledge. All this opens up un-
imaginable ethical scenarios, which go far beyond the issue of saying ‘yes’
or ‘no’ to the embryo. Such scenarios connect the ‘do-it-yourself’ of local
practice in many laboratories all over the world, with ethical and political
issues yet to be conjectured.
     In conclusion, two issues seem to emerge: firstly, the quest for stabili-
zation of stem cells knowledge; secondly, the type of symmetry between
stem cells science and the social issues that arise.
     Stem cells research contributes to produce a variety of experimental
studies, various artefacts and many research questions. This plurality of
scientific resources sustains and fosters diverse issues, being them scien-
tific and technical, ethico-social or a mix of both. These are closely relat-
ed to the specific fields to which stem cells are anchored, from the view-
point of their use and development. Among these are the study of cellular
148                                                          Tecnoscienza - 4 (1)

and genetic processes, the modelling of particular diseases, the experi-
mentation of differentiating protocols and cellular reprogramming, cellu-
lar transplantation and others. Therefore, no single field of stem cells
knowledge exists, rather there are multiple fields producing rhizomatic
segments, all in search of experimentation, reliability, recognition and
standardization. This happens because stem cells, in all their biotechno-
logical inscriptions, activate multiple, non-converging research questions
and diverse forms of stabilization (or non-stabilization).
    Given their impact on sensitive and ethical knowledge, stem cells are
especially linked to the issue raised by Giuseppe Testa regarding the val-
ue-based commitment to which science is subjected. Scientific knowledge,
as directly and explicitly motivated by an external value-oriented custom-
er base, attempts to manoeuvre, and to solve, the ethical and political is-
sues which emerge on a technical level. However, according to the two
interviewees, it does not seem that this element alone succeeds in con-
tributing to the development tout court of stable, reliable, exportable and
converging knowledge in the biotechnological field. Further issues arise
when knowledge is commissioned from scientific practice by external eth-
ical requests, as in the sensational case of the stem cells produced by Al-
tered Nuclear Transfer. These issues are not easy to address, because it
becomes necessary to demonstrate both the ethical nature and the achiev-
able results of the knowledge, no simple task in a practical context. The
combination of these and other stem cells research pathways, stimulated
by scientific and ethical cases from within scientific practice (such as the
case of embryonic stem cells, rather than iPS), contribute to producing
fields of knowledge which, far from being alternatives or juxtaposed, im-
ply a plurality of technoscientific options with multiple potential applica-
tions in the biomedical field.
    These pathways open up scientific panoramas which are perhaps not
immediately applicable, but which attempt to answer ethical issues, mul-
tiply research questions and to build future scenarios. One without the
other is unthinkable, one calls out to the other, and generates it. The plu-
rality of research into stem cells is activated in reply (or posed as a ques-
tion) to the plurality of ethical issues the bench puts to the test: it is
knowledge in search of stabilization which in the meantime opens up
prospects, questions and visions of the future.
    As Geesink, Prainsack and Franklin affirmed in 2008, “for stem cells,
the future is now”, but it can also be said that, at the same time, the fu-
ture has not been written yet. We are taking part, or will take part, as our
interviewees say, in a mutual adjustment of scientific practice capable of
generating multiple biological artefacts and their multiple ethical implica-
tions. Perhaps this will contribute to building a more biotechnologically
mature society.


                                      ***
Cattaneo, Testa, and Viteritti                                                  149


2. iPS, Bioscience and Value-oriented Customer Base
     Giuseppe Testa received a PhD in Biology and Molecular Genetics from the Eu-
ropean Laboratory of Molecular Biology (EMBL) in Heidelberg with a thesis on ge-
netic engineering. He runs the epigenetic stem cell laboratory at the European Onco-
logical Institute in Milan. His research focuses on the mechanisms which regulate
stem cells differentiation in order to develop new regenerative therapies. He has
done scientific work at the Max Planck Institute of Molecular Biology and Genetics
at Dresden University and in other leading research centres in Europe, the US and
Japan. In 2002, he founded the Science and Society Forum at the Max Planck Insti-
tute with a view to promoting awareness and debate on social implications of bio-
technology. He went on to achieve a Master’s degree in Bioethics and Biological Law
at Manchester University. At the John Kennedy Faculty of Political Science at Har-
vard University, he was visiting fellow lecturing on the legal and political implica-
tions of biotechnologies. Author of numerous publications on genetic engineering
and human disease models and studies of science and technology, he has received
significant recognition including an honorary PhD in Biotechnology awarded by the
European Association of Higher Education in Biotechnology (HEduBT) for his ex-
cellent research in the biotechnological field.

AV – Can you tell me how you came to tap into stem cells in your scientific
work?

GT – It happened in 1997, after graduating, when I began my doctorate
in Biological and Molecular Science at the University of Milan (the
EMBL). At the time, stem cells were fundamentally a tool for producing
mice with which we could study illnesses and reconstruct the functionali-
ty of genes. My PhD project involved leukaemia in mice, and I used a se-
ries of new techniques which adopted embryonic stem cells to produce
mice. In that phase, the stem cells were a tool linked to man in a very in-
direct way. Up to ’98-‘99 embryonic stem cells fundamentally remained a
working tool for research on mice. A lot of people thought that they
would remain a kind of oddity, for a whole series of reasons including
ideological ones, an idiosyncrasy in mice which wouldn’t necessarily be
found in other species. In ’98-‘99, though, human embryonic stem cells
burst onto the scene, with all their new potential. An ethical/political con-
troversy (which has also produced a wealth of STS literature) erupted and
brought the bioethical conflict in western society to almost unheard-of
levels of prominence. The day after the news about the Dolly cloning was
announced, Clinton declared: “We must stop this from happening”.
There’s a political investment in this we’ve never seen on other occasions.
Naturally, those years were filled with great ferment, in the quest for that
which I would have called in an article some years later the “Holy Grail”:
everybody hoped to get an embryonic stem cell without having to start
from the embryo – some for ethical reasons, some for reasons of mere fea-
sibility. Many said it would be impossible, that you would need to change
150                                                         Tecnoscienza - 4 (1)

too many things to take a differentiated cell from our body, like skin or
neurons, and make it into an embryonic stem cell. So in 1996, when I was
at the first conference in which Yamanaka presented the data on iPS be-
fore it was published...I remember as if it were today the mix of excite-
ment, sheer bewilderment and also great disbelief on the part of some.
Then, too, the experiment had been carried out on mice. Ten years later,
in 2007 (after Dolly), human iPS are generated. In ten years the prospects
of regenerative medicine changed completely, and above all also changed
the prospects regarding the role of medicine in making models for the
disease. Today, fifteen years later, I find myself running a laboratory in
which human iPS are used to model diseases.

AV – So you switched your focus from embryonic stem cells to iPS…

GT – Yes, we have never used human embryonic stem cells in the labora-
tory, but murine embryonic stem cells as scientific objects to be studied in
themselves, their differentiation, above all in the neural line. After Yama-
naka’s work, we moved on to reprogramming through mouse iPS to study
the epigenetic mechanisms which allow a cell to change its identity – sur-
prising at that time, but not anymore. The other passage was moving on
to human iPS. This time we don’t use them to study the reprogramming
mechanism, but as models for diseases. We reprogram patients’ fibro-
blasts in iPS cells and we differentiate them into neural stem cells of the
cortex, because cortex neurons are involved in autism and mental defi-
ciency, the two illnesses we study.

AV – In your opinion, do iPS solve the ethical problems arising from em-
bryonic stem cells, or do they create new ones?

GT – iPS don’t solve the ethical problems, they pose several. They cer-
tainly allow us to do practically everything we want with our body, at least
potentially. They open up a whole scenario of social, political and ethical
options. For example, according to the Athens Group’s last Consensus
Conference, which I took part in some years ago, based on the results we
have already obtained it’s highly probable that in ten years time (bearing
in mind the limits which always invest scientific prophecy and all neces-
sary caution) we shall be able to produce functioning gametes from iPS
cells. This means that we can take reproductive cells from the skin, for
example. Given that the cost of sequencing DNA has fallen dramatically,
we can hypothesize for the first time the mass production of embryos in
vitro and the screening through sequencing. It’s therefore difficult to say
whether iPS either solve or create ethical problems. In the first place, I
should say that there are technical issues. For example, they present a se-
curity problem linked to how they are generated. Our laboratory, for ex-
ample, is one of the seven or eight in the world chosen as a reference
point and where we use only the technique based on mRNA. This means
Cattaneo, Testa, and Viteritti                                          151
that we don’t use viruses anymore…and this is an enormous step forward
because we avoid integrating the virus into the cells, so we avoid a whole
series of risks to the genome’s integrity linked to the use of viruses (...)
Furthermore, the more profound aspect is: how well do we know how to
control iPS in vitro? If we want to use them to understand certain illness-
es at specific stages of cells development, how do we know that these are
the right ones? A lot remains to be done on this, because it’s a job which
involves the standardization of cellular models, to use the correct terms
(...).

AV – What’s the story behind ethical stem cells? How was this term coined
and how is it used in Italy?

GT – It’s talked about a lot in Italy. Every so often articles are published.
There has even been talk of the Italian pathway to stem cells, but I’ve
rarely heard the word “ethical” associated with stem cells in America. Of
course, people speak of ethical solutions to the issue of stem cells. This
story started in America, and was an attempt on the part of some bioethi-
cists, politicians and investors to solve the bioethical controversy (...). A
first example of what became known as ethical stem cells were the cells
produced through Altered Nuclear Transfer (ANT), which became well-
known also thanks to my work. In the American bioethics committee ap-
pointed by George Bush, there were people who opposed embryonic
stem cells research and among them was a bioethicist doctor who called
for the production of ethical pluripotent stem cells. He would never call
them “embryonic” because they possess a certain type of genetic breaker
which removes a gene from the future embryo. Without this gene the pla-
centa does not develop. You start from the oocyte, the nucleus: at the
time, there was talk of cloning. You remove this gene from the nucleus of
a somatic cell, from the skin, for example, and then you insert an oocyte.
Development commences, but it can never be successful because an es-
sential component is missing. In my opinion, this example appears very
interesting, this first triangulation is extraordinary: a bioethics committee
(which in America is appointed by the President and is, therefore, a direct
emission of executive authority) explicitly delegates to science the finding
of a technical solution to a moral issue. In this, the U.S. have been very
honest: a political solution cannot be reached, so let’s seek a technical so-
lution which can also solve our political problems. An artefact which is
not an embryo, because it has never become an embryo and will never do
so, is therefore produced. This idea from the bioethics committee is
commissioned and translated into fact in the laboratory and subsequently
published in Nature and this artefact is rendered morally legitimate by
imitating nature, which is elected as the source of responses to dilemmas
regarding values. We know that many episodes of natural insemination
are unsuccessful because the embryo develops but does not take root:
these precocious failures are a part of nature. In the ANT project we pro-
152                                                         Tecnoscienza - 4 (1)

pose a kind of imitation of these natural failures in the laboratory. This
brings us to an interesting point: who can say that also the end product of
this strategy is never an embryo? What if I were to tell you that it starts
off as an embryo, but then on the fifth day it dies because it needs that
gene and it can’t find it because it has been removed? As a matter of fact,
this doubt induces the American bioethics committee to fly over from
Germany one of the greatest scientists in the stem cells field and ask him:
“How many genes need to be altered in order to be sure that this thing
we’ve produced is no longer an embryo?”. To me, our whole era lies in
this question…

AV – Has the knowledge gleaned from Altered Nuclear Transfer (ANT)
become accepted? Does anyone work with them?

GT – The work was published, and in 2005 ANT became a technological
object. However, this was in 2005, and one year later, in June 2006, Ya-
manaka began to speak of iPS. I would say that the ANT story is well and
truly over, even though it’s an interesting one, rich in implications. Today
nobody works with ANT anymore, but the idea of “value-oriented cus-
tomer base”, of scientists who are more and more engineers for commis-
sion, has become more of a reality, to a point where Yamanaka affirms in
his first article that the driving force behind his accomplishing what eve-
ryone thought impossible, i.e. iPS, is also an answer to the ethical issues
surrounding embryonic stem cells. That’s what he says today.

AV – So there’s also a kind of value-oriented customer base research? A
demand which doesn’t arrive directly from the workbench, but arrives at the
workbench...

GT – I’ve cited the stem cells case as an example of how scientists be-
come the executors of a value-oriented customer base, like an engineer or
an architect who builds a bridge or a prison to order, in various articles.
Of course, according to whether you build a prison or a bridge, the value-
based commitment to helping people communicate or keeping them
locked up is materially inscribed into that work. The political establish-
ment says to the scientist: “Create a stem cell according to value-based
criteria, using the latest biogenetic engineering techniques, so that your
product doesn’t give me any moral problems”. The scientist goes into the
laboratory, does this and publishes the outcome in the most prestigious
journals in the world, also conferring an official stamp of recognition to
his/her discovery. In my opinion, this is an example – not necessarily the
only one, but surely absolutely unprecedented in this field – of explicit
value-oriented customer base. The bio-scientist or biologist, however you
want to call him/her, becomes the executor of a program of values. This
is the most interesting aspect of iPS, over and above whether we’ve solved
the ethical issues or not...
Cattaneo, Testa, and Viteritti                                            153


AV – But today it’s iPS that have this ethical label...

GT – I don’t think that embryonic stem cells present any ethical problem
whatsoever. There are vast segments of our society that don’t think so ei-
ther. Undoubtedly, iPS don’t need a human embryo produced by in vitro
fertilization. There’s a huge ongoing debate about this, and I’ve taken
part in it with an article written together with two of my students in the
“American Bioethics Journal”. The classic argument of the bioethicists
who oppose the use of embryos is that of the potential: “It’s not the em-
bryo itself that needs to be respected, but we must respect it because po-
tentially it could become a person”. However, Yamanaka’s experiment
definitively demolishes the argument of the potential, as I demonstrated
in my article in “Stem Cell”, and shows how it is open to attack in many
ways. After the Dolly cloning and Yamanaka’s work, some bioethicists
raised doubts. If every cell has this potential and all that’s needed is to
make it manifest, this is the tombstone on the argument of the potential,
unless you want to maintain the necessity of taking care of all our cells
because they’re all potential people. Therefore, I and others maintain that
rather than closing the bioethics issue, as many would have wished, Ya-
manaka’s experiment opens it up because it poses a problem linked to
potentiality, transforming it into a property which is not associated with a
certain type of cell, but with a cellular state which is somehow inter-
changeable. Of course, ethical problems have also been posed regarding
embryonic stem cells. One of these was the De Coppi case, which Elena
Cattaneo also mentioned in an article. This regards the theme of amniotic
liquid stem cells, which were declared to be ethical by their discoverer.
Before Yamanaka, embryonic stem cells bore the stigma of immorality,
not only in Italy but worldwide. Therefore, any attempt to do the same
things with other types of stem cell, including amniotic stem cells, was
hailed as the ‘Holy Grail’. These stem cells have been criticized too,
though, by Elena Cattaneo herself and other scientists: although they are
said to have the same properties as embryonic stem cells, it seems that
with amniotic ones it is not possible to differentiate neurons.

AV – This multiplicity of bio-objects would seem to allow and give voice to
the articulation of a multiplicity of ethics as numerous as the multiplicity of
ontologies produced with stem cells...

GT – Exactly. One thing is certain: there is a plurality of ethics. At a time
in which life sciences become more and more a kind of engineering do-it-
yourself, assembling and disassembling, evidently an even greater plurali-
ty of customers becomes possible. If I think that the human embryo pos-
sesses a moral dignity right from the first day, I’ll ask the scientist to imi-
tate natural failure in vitro; or, for example, believing according to Mus-
lim precepts that the soul arrives on the fortieth day, I’ll ask for an em-
154                                                          Tecnoscienza - 4 (1)

bryo that stops developing on day forty.

AV – But do you believe that iPS are replacing embryonic stem cells in the
laboratory?

GT – Mainly, yes, but there’s still a need for standardization and to have
embryonic stem cells as a reference point, both for some demands of
basic biology and for many prospective applications, to have the possibil-
ity of comparing iPS with Human Embryonic Stem cell. Having said this,
there are many human stem cells, and many lines in the world. Some of
them are well-known and standardized, so they are used as a reference
point. Embryonic stem cells can be taken from embryos in vitro, generat-
ed in the majority of countries during assisted insemination attempts
when the couple involved permits the donation of embryos. This limits
the choice of the type of stem cell which can be obtained: the number of
embryos is very limited, above all in the case of rare diseases such as Hun-
tington’s, for example. For this, iPS are extraordinary: if you want to
study diabetes, you select fifty patients with diabetes so that they have the
clinical characteristics which correspond to the requirements for the
study, and produce the iPS from them. Therefore, in the study project
you have a possibility of prospects which you can never have with embry-
onic stem cells. Today, iPS are both a point of arrival and departure.
Human embryonic stem cells represent a gold standard reference point,
but undoubtedly the further we go on, the more and more important iPS
will become. In a context of STS sensitivity, embryonic stem cells repre-
sent a gold standard today in that they are a natural model but produced
in the laboratory, given that the embryo is in vitro, transited in culture.
Pluripotency, which is a property of the embryo in vivo, is captured in
vitro. They seem more natural, while others (iPS, for example), seem
more artificial, and for certain aspects they are: even though they are ex-
tracted, cultivated, etc., they undergo a process which is in itself unnatu-
ral. Therefore, embryonic stem cells are the natural gold standard, but as
we go on, the more problems we pose regarding this notion, the sooner
the day will come when we use only iPS. It’s a natural process, and as
Latour said, it’s both a point of arrival and departure.

AV – In your opinion, which of the stem cells pathways is the most promis-
ing today?

GT – I should say that the first road is that of modelling diseases. In the
history of medicine, our capacity for understanding human diseases has
until now been limited by one important factor: that of accessing the pa-
tient’s tissue, for obvious reasons, because it’s in a person’s body. Fur-
thermore, the problem is accessing it in phases which make sense: for ex-
ample, there are many brain banks, but of course of brains post-mortem.
Obviously, for some illnesses this lack of material is less serious: blood
Cattaneo, Testa, and Viteritti                                                 155
disorders, for example, which historically are those where the greatest
progress has been made. But as far as disorders of the brain or other or-
gans are concerned, we have been unable to gain access for a long time,
and our only tool for modelling diseases has been the mouse. However,
it’s obvious that the mouse as an organism is intrinsically limited, above
all because it doesn’t give us the possibility of studying how human genet-
ic variability contributes to diseases, unlike iPS (and this represents the
great innovation of iPS). For the first time in the history of medicine, iPS
allow us to tackle human genetic variability experimentally. For the first
time, you can take an unlimited number of people with the same patholo-
gy, or differing degrees of the same pathology, and finally ask the ques-
tion: “What contribution does their genomic variability make to this pa-
thology?” (...). Of course, as this intellectual and practical challenge goes
on, large-scale experiments for the pharmacological screening of these
cells have already begun, and this is perhaps a sign of our times. In these
cases, the area of application is certainly most promising. Then there’s the
other story, making Prometheus’ dream come true: the idea that with iPS
research we can make our skin a bank of replacement organs. One day
we’ll be able to take skin cells, or even hair cells, and produce in vitro first
cells, then tissue, then one day organs, which at that point – being genet-
ically identical to us – can repair, replace or maybe in the future even im-
prove parts of our body without any problems of rejection. Obviously,
there are a series of motives which can easily be understood and which
are linked to the security of these approaches and an all-important level
of regulation, as well as the feasible application of all this in a healthcare
system. Let’s say, however, that this future prospect, Prometheus’ fron-
tier, is what I can certainly see on our horizon, albeit one which is still far
off.

                                        ***
3. Scientific Reasoning and Plurality of Ethics
Elena Cattaneo, PhD in Biotechnology from Milan University, studied stem cells
and brain progenitors at MIT in Cambridge, USA. On her return to Italy, she con-
tinued her stem cell research and started up new lines of research into Huntington’s
disease. In 1994 she founded her laboratory at the Faculty of Pharmacy in Milan,
where she has been full professor since 2003. She founded the Unistem Stem Cell
Research Center at the University of Milan. For many years her laboratory has been
a member of the “Coalition for the Cure” promoted by the Huntington's disease So-
ciety of America (H.D.S.A., New York) and has taken part in research activities on
behalf of the Hereditary Disease Foundation (H.D.F., Santa Monica, California).
She has published many works on stem cell research and Huntington’s disease, and
among the numerous awards she has been given are the “Science award for Medi-
cine” (2001) and the Italian Presidential Medal, which she received from Carlo Aze-
glio Ciampi. In 2002, she was nominated National Representative at the European
Union for Genomic and Biotechnological Research (2003-2006) by the Ministry for
156                                                             Tecnoscienza - 4 (1)

the University and Research. In 2007 she took part in the National Committee for
Bioethics both as a member and Vice-President. From 2009 she has been coordinator
of the European NeuroStemcell project funded by the 7th European Research
Framework Program.

AV – Was your laboratory the first in Italy to use human embryonic stem
cells?

EC – I believe so: in 2005, and later on with the EuroStemCell project,
we were the first in Italy to receive ethical approval regarding the use of
these cells at Milan University. Then, still in 2005, there was a referendum
on medically assisted procreation, which set limits for embryonic research
and posed some problems. At that time I was vice-president of the Na-
tional Bioethical Committee, and I think the fact that I stated we used
embryonic stem cells in my laboratory didn’t go down well. In Italy, the
limitations regarding the use of stem cells have always been those im-
posed by Law 40 on medically assisted procreation, which states that we
cannot derive them ourselves, but we can obtain them from abroad and
import them, as we did, in the context of the several international collab-
orations and EU-funded research consortia we belonged to. What really
annoyed me for some time at the beginning was the code of silence, even
among several of my colleagues: some of them came to my laboratory to
try, understand and learn to use these cells, but when they should have
spoken out and said that they used them in their laboratory work in Italy,
most of them kept their mouths shut. I didn’t want to be the one who got
around the law and went abroad, but I wanted to eradicate the idea that a
good scientist doesn’t use stem cells and an unethical one does. In my
opinion, this was and remains a trivialization of values. Therefore, with
the referendum in 2005 I engaged with the Italian Radical party as I
wanted to help them getting things the right way (...) initially in public
they were declaring that it wasn’t possible to work with stem cells in Italy
and it wasn’t true. Instead, I wanted people to know that we could legally
work with these cells and I wanted people to know why I wanted to work
with these cells.

AV – Because it wasn’t true that it was impossible to work with embryonic
stem cells in Italy, and at that point you stated your position publicly.

EC – Yes, of course they could be used in Italy and I didn’t want to be
branded with the mark of the unethical scientist. I wanted to express my
opinions, explain the whys and wherefores. There was a vote and the ref-
erendum was lost and then immediately afterwards I was appointed to the
National Committee for Bioethics in 2006. I believe I was chosen because
I represented a certain stance, a scientist who both stated she used them
and declared herself to be a Catholic. In the course of that year I orga-
nized a convention here in Milan and a public issue arose. I was vice-
Cattaneo, Testa, and Viteritti                                             157
president of the National Committee for Bioethics and Casavola, a Catho-
lic jurist, was still president, and at a certain point he fired the three vice-
presidents, including myself. I read in a newspaper that I was dismissed. I
remembered talking with the president on the phone when I was nomi-
nated, as I wanted to make sure that he regarded as valuable for him and
for the Committee to have a scientist as vice-president. Acting as vice-
president was not a favour, for me. I remember approving the fact that
the president of the Committee for Bioethics was a jurist, it gave me the
feeling he was principled, someone who would seek the truth. I thought,
however, that after being on the receiving end of a public attack at the
convention in Milan, a plot hatched somewhere to make me bear the
brunt: I was the one who used stem cells in my laboratory (...). I remem-
ber that one day, the Catholic jurist Francesco D’Agostino arrived at a
meeting and said: “Scientists have published this article on amniotic stem
cells. That’s it! Embryonic stem cells get shelved!”.

AV – How many scientists sat on the Committee?

EC – Myself, the pharmacologist Silvio Garattini and Emilio Piazza, a ge-
neticist from Turin. In February 2007, there was an international work-
shop on embryonic stem cells in Milan and patently organized pandemo-
nium ensued. I was harshly attacked by some Catholic students whom I
later met and clearly understood to be incapable of having done every-
thing by themselves. The message was directed straight at me, I knew I
was their target because the convention had been organized by Fulvio
Gandolfi2 and myself. Had the convention itself been the target, the letter
which was later made public would have been sent to the organizers, but
I think I was their target because at the time I was the only declared
Catholic who was both a member of the National Committee for Bioeth-
ics and worked with embryonic stem cells. The public letter, which also
appeared in the press asked “How can you work with embryonic stem
cells without asking yourself what an embryo is? Isn’t it human life?”. Af-
ter becoming publicly involved I remained silent for weeks before reply-
ing in the national press. I consulted a lawyer and tried to understand
whether there was anything I needed to protect myself from: he told me
that at that moment there were no grounds for appeal, to stay alert. We
spoke again, I paid his fee and stop. The story then appeared in the press
and continued to circulate because something like this is fairly unusual in
the university environment. And when you are in the middle of something
like this you immediately realize that you are alone and that some people
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2
  Expert in embryonic stem cells and the reproductive sphere. Full professor at
the Faculty of Veterinary Science where he teaches Embryology and Genetic and
Cellular Therapy, head of the Laboratory of Biomedical Embryology and one of
the four founders of the Interdepartmental Center for Stem Cell Research – UniS-
tem – at the University of Milan.
158                                                               Tecnoscienza - 4 (1)

were enjoying this. I felt sick. I had colleagues accusing me of having
brought politics into the university. I felt really left out in the cold but I
received support from colleagues from different departments in Italy.
This happened in February, then came March, April... I went back and
forwards to the Committee in Rome every month and then in July Casav-
ola fired the three vice-presidents and a month later I appeared before
the Committee and asked to make a speech. I said that although I had de-
cided to leave the Committee, before doing so I wanted to speak my
mind. My speech can be found on the net3. I began by saying that I failed
to understand how nothing should be said about us being dismissed: I
had offered my services to the Committee without payment, taken on a
lot of extra work as well as taking part in the meetings. Then I was
thrown out of the vice-presidency on my ear and for no clear reasons, to
my view, and nobody had anything to say. I started my speech and I went
on to speak for 45 minutes. I said all I had to say, trying to reason things
out, I mean, why what the President had done that wasn’t right, then I
resigned according to a text, which has since become public knowledge.
This was in October 2007.

AV – There was another story which saw you in the public eye, one also
linked to the embryonic stem cell research theme …

EC – This second story dates back to 2009, when a public tender notice
regarding stem cells and their therapeutic prospects was issued by the
ministry. My colleague Giuseppe Testa summarized all this in his contri-
bution4 in a curious way, as he linked our case (I carried it out along with
two other scientists, Silvia Garagna e Elisabetta Cerbai) with that of two
American researchers who opposed the Obama administration because it
had come out in favor of embryonic stem cells. He put the two cases to-
gether and said that here in Italy there are researchers who aim to open
up the research field to stem cells, while in the US those two researchers
were tending to close it. A good piece. It was a tender notice from the
Ministry of Health on stem cells and their potential application which in-
cluded this phrase: “No embryonic stem cells”. We contested this5. In any
case, why should a government decide what scientific means can be used
to achieve a goal? The government defines the aim, the means are up to
the specialists, also because Law 40 permits the use of human embryonic
stem cells. They are scientifically relevant, and blocking a scientist from

!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
3
  http://159.149.74.38/webpage/Scandali/Cattaneo%20CNB%2026%20Ott%20
2007.pdf
4
   Testa, G. (2012) Stem Cells and the Structuring of the Italian Biopolity, in R.G.
Mazzolini and H.-J. Rheinberger (eds.), Differing Routes to Stem Cell Research:
Germany and Italy, Bologna and Berlin, il Mulino/ Duncker & Humblot, pp. 225-
249.
5
  http://www.unipv-lawtech.eu/files/Appello_staminali_finale_CdS.pdf
Cattaneo, Testa, and Viteritti                                            159
doing research that is scientifically relevant and legal to me is an abuse of
power. Anyway, we took legal action, we appealed to the court. Silvia
Garagna is from Pavia, and she told me this issue cost her a lot. Together
with colleagues at Besta Neurological Institute and Stefano di Donato6 I
had prepared a project and submitted it to that tender notice. In the
meantime, we had requested a suspension, so you have to go to the Re-
gional Administrative Tribunal to get the tender notice suspended and
they decide whether it is valid or not. The Regional Administrative Tri-
bunal refuses our request for a suspension, so we take it to the Council of
State where it’s refused again six months later. In the meantime the ten-
der notice is published, and on expiry the money is assigned and we are
left with our ideas in the drawer (…).

AV – And was the project you presented ever evaluated? Did anybody ever
tell you anything?

EC – We never heard a thing. I had also written an accompanying letter
in which I said that we were submitting, but were aware that, etc., etc.
From a legal viewpoint, the two steps we took (Regional Administrative
Tribunal and Council of State) requesting a suspension never got as far as
the Tribunal, so the issue is still open. Six months ago our lawyer told me
that they’ve got five years, and just continue to postpone it. I don’t know
whether this is because they’ve got better things to do, at this point the
tender notice has already expired, the money has been assigned, the pro-
jects carried out and we haven’t heard anything (...). I want my lab reim-
bursed by the State, as the State has prevented our ideas from being eval-
uated. The absurd thing is that in another national tender, a PRIN call for
proposals, we stated that we use stem cells for our research... and we were
funded. This aspect reminds me of the case of a German colleague, Oli-
ver Brüstle, (this story too is narrated well in the book containing the arti-
cle by Giuseppe Testa). In 1997, before the discovery of human embryon-
ic stem cells, Oliver submits a patent for one of these differentiation
methods. However, he had also foreseen the use of other cells, and the
patent was extended to cover human embryonic stem cells, which in the
meantime had been discovered. The patent process goes ahead, and when
it reaches the European Patent Office it’s blocked because in the mean-
time Greenpeace has sued Oliver because his patent is contrary to public
order with reference to the EU directives on biotechnologies, which state
that the human embryo cannot be patented. But these aren’t human em-
bryos, they aren’t even cells, but only a differentiation method (...).
Greenpeace sues and the case arrives in the German Federal Court,
which decides not to make a ruling but to consult the European Court of
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
6
 Dr Stefano Di Donato, MD, was Chairman of the Department of Research, and
Director of the Division Biochemistry & Genetics at the Istituto Nazionale Neu-
rologico Besta, Milan.
160                                                         Tecnoscienza - 4 (1)

Justice in order to find out what an embryo is. The European Court of
Justice rules that the embryo and its derivatives cannot be patented.
Therefore, following this logic, neither can anything connected with the
product of conception, neither can you research and patent contraceptive
methods (...). In any case, from a patent point of view, Germany still has
to decide what to do, they’re agonizing over this, there the case is pro-
ceeding, like in every other State (...). In Europe we may lose 300 patents,
I believe all the European patents will expire: just think how happy they
are about this in the US. They’ve killed off all the European patents
linked to cultivating human embryonic stem cells, so obviously you can
decide to patent them in the US or Japan. Oliver’s story sure is crazy.

AV – At a certain point, research fields which try to get around the embryo
issue developed. There’s talk of ethical stem cells. What can you tell me
about this?

EC – The story starts in the US in 2004, I believe, with some senators…I
think the first was a senator or an expert from the ethics committee…and
he says: “What if we create a blastocyst which has mutated?”. It was a
senator who clearly had an interest in the matter. So if we create a blasto-
cyst which is mutated and can’t take root in the uterus, this is ethical, it
doesn’t involve the embryo, we can isolate embryonic stem cells from
such an entity. This issue was linked to therapeutic cloning, and the aim
was to get the cells you want, so embryonic stem cells too, from a source
believed not to be a person. Therefore, you modify this source so that it
can never become a person. This was right in the middle of the Bush ad-
ministration. Some scientists take cells from the skin of a mouse mutated
for the gene which would make the blastocysts take root, they extract the
nucleus, they put this nucleus in an oocyte with the nucleus removed, so
now this is like therapeutic cloning. However, this oocyte with a new nu-
cleus develops a blastocyst, which is mutated because the gene, which
would make that blastocyst take root, has been cancelled from the origi-
nal nucleus. They extract the embryonic stem cells with the idea that the-
se are ethical because they’re derived from a de-nucleated oocyte (...)
there was a good commentary on this in the “New England Journal of
Medicine” in 2004, which spoke of disaster in the distorted relationship
between science and politics.

AV – Does this ethical stem cells theme involve other research teams, per-
haps also Yamanaka’s?

EC – Yes, of course, also Yamanaka. He has always said that an experi-
ment published by others made him curious. At that moment people
were looking for solutions, to my view not because they were ethical or
non-ethical, but because they weren’t able to go ahead with therapeutic
cloning. If you take the stem cells, the fibroblasts and you unite them
Cattaneo, Testa, and Viteritti                                               161
with embryonic stem cells by using an adhesive, then you get bigger cells.
However, the most interesting thing is this nucleus – that is, you pretend
you have two nuclei – this nucleus is reprogrammed. So he says that when
the two cells are placed in contact, inside there’s stuff which reprograms
the nucleus of an adult cell, and that’s where he got the idea of repro-
gramming. He evaluated what can be in there, and started with 24 genes.
Yamanaka says that reprogramming helps to avoid the ethical problem
but he also says that we need human embryonic stem cells (...). When I
travel around the world to conferences, this topic is not an issue, among
scientists it isn’t discussed like this, ethical stem cells and things like that
are not spoken of. The so-called ethical stem cells are not an issue in the
laboratory, but a public issue. Yes, maybe it’s a topic for some scientists.
For me, the ones that I have are ethical, and I don’t know why I should
have to find others. They are ethical and they produce the neurons we
want to know more about Huntington’s disease. No other stem cells can
do it better nowadays. This idea of ethical stem cells assumes that some
scientists are working with non-ethical stem cells, that some scientists are
not ethical. That is, one can say that they don’t work with embryonic stem
cells because in his or her opinion they aren’t ethical, but that doesn’t
mean they think that those who use them aren’t ethical. Then again, in
the application field no distinction is made between ethical and non-
ethical. I can’t remember a conference in which this was a topic for dis-
cussion, this is an ethical-philosophical debate, not a scientific one. I un-
derstand perfectly that society has the right to say ethical/non-ethical, or
things like that, but in science we try to pursue things that work, that
have reliable, rational prospects. And I see a lot of ethical values in this.
That senator’s famous experiment was binned despite the fact that it was
published in “Nature”, because it wasn’t supported by scientific reason-
ing. It’s obvious that if you mutate a gene from a blastocyst and you know
from a whole load of experiments that it won’t take root, where’s the sci-
entific strength in this? The value to be found in experiments is their sci-
entific result: of course, if in future we have an amniotic stem cell, and
they tell me it’s ethical, and I can extract a wonderful neuron from it, I’ll
certainly work with it. Now, however, I certainly can’t get the neurons I
need for my studies on the disease from amniotic stem cells, and I want
results, so I pursue them: if they’re real, useful, credible results I pursue
them (...).

AV – However, some scientific objects have thus been labeled...

EC – Whether they survive or not, it doesn’t depend on their ethical la-
bel, but on their scientific value (...). In all sincerity, I find it difficult to
imagine future scenarios, unlike many of my colleagues who are able to. I
have to take one step at a time, and from what I see I should say that I
think we still have to learn from methods of differentiating embryonic
stem cells and they will continue. With regard to iPS, of course I’m very
162                                                               Tecnoscienza - 4 (1)

curious to see how they behave. In my opinion, the key factor is that you
take a mature cell and its genome and you can reprogram it into the la-
boratory and if you speak with the clinician, the clinician has all his clini-
cal data. The innovation is in this combination of laboratory and clinician,
more than in the cell itself. From a clinical point of view, they’re really
studying Huntington in a huge number of ways and they’re coming up
with extraordinary things with regard to symptoms (...) this means that in
the genomes of different patients, there is something that distinguishes
them, which is outside the gene: if you place their tissue, their cells, their
genome in vitro, perhaps you find a method for studying things that you
can’t even imagine in vivo. You try to understand how they can be differ-
ent as regards age at onset, because if you find this out you push the one
with the first onset twenty years on, which is usually the timescale of the
disease. If it’s in the genome you take it to the laboratory and you study it
with the iPS, differentiating the neuron, etc., and what distinguishes the
two genomes and what functional aspects distinguish them: however, in
order to work well with iPS, you must be familiar with embryonic stem
cells (...). Then there’s the big issue of cellular reprogramming as scien-
tific knowledge, there’s this DNA, which unravels and begins to talk. This
is disturbing, aside from the therapies and the illness, this is scientific
knowledge to be placed on a pedestal (…). With stem cells or iPS you can
intervene in the process of cellular development in every direction. This
means you can modify the cells’ destiny. This word, destiny, is the one
we’d all like to hold in the palm of our hand, and in the laboratory you
can hold it in your hand and here they attack you saying you’re a scientist
who wants to modify cellular destiny so you become like Frankenstein.


References
Bowker, G. C. and Star, S. L. (1999) Sorting Things Out: Classification and Its
Consequences, Cambridge, MA, MIT Press.
Eriksson, L. and Webster, A. (2008) Standardizing the Unknown: Practicable Plu-
    ripotency as Doable Futures, in “Science as Culture”, 17 (1), pp. 57-69.
Geesink, I., Prainsack, B. and Franklin, S. (2008) Stem Cell Stories 1998–2008, in
   “Science as Culture”, 17 (1), pp. 1-11.
Knorr Cetina, K. (1999) Epistemic Cultures: How the Sciences Make Knowledge,
   Cambridge, MA, Harward University Press.
Le Roy, W. (2004) Human Embryonic Stem Cell Research: An Intercultural Per-
   spective, in “Kennedy Institute of Ethichs Journal”, 14 (1), pp. 3-38
   http://muse.jhu.edu/journals/kennedy_institute_of_ethics_journal/toc/ken14.
   1.html
Sleeboom-Faulkner, M. and Simpson Durham, B. (2013) Experimental Ethics:
    Emergent themes and issues in life sciences research in Asia, in “BioSocieties”,
Cattaneo, Testa, and Viteritti                                               163
    8, pp. 2-6.
Testa, G. (2008) Stem Cells through Stem Beliefs: The Co-production of Biotechno-
   logical Pluralism, in “Science as Culture”, 17 (4), pp. 435-448.
Testa, G. (2012) Stem Cells and the Structuring of the Italian Biopolity, in R. G.
   Mazzolini and H. J. Rheinberger (eds), Differing Routes to Stem Cell Research:
   Germany and Italy, Bologna and Berlin, il Mulino/Duncker & Humblot, pp.
   225-249.
Timmermans, S. and Berg, M. (2003) The Gold Standard. The Challenge of Evi-
   dence-Based Medicine and Standardization in Health Care, Philadelphia, Tem-
   ple University Press.
Vermeulen, N., Tamminen, S. and Webster, A. (eds.) (2011) Bio-objects. Life in
   the 21st Century, Farnham, Ashgate.
